PDCD1LG2 and interstitial lung disease: The difference in the occurrence of ICI-ILD under treatments with anti-PD-L1 antibody and anti-PD-1 antibody might be influenced by the differential inhibition of interaction between PD-1 and PD ligand-2 (PD-L2)15.